Skip to content

Stereotaxis STXS Depreciation

Depreciation at other companies

Stryker logo
StrykerSYK
$120M+14.3%
Abbott logo
AbbottABT
Neuropace, Inc. logo
Neuropace, Inc.NPCE
NVE Corporation logo
NVE CorporationNVEC
TFX
TeleflexTFX

Other financials

Income statement

See full
Revenue$6.3M-15.8%
Gross profit$3.8M-6.6%
Operating income-$6.0M-0.9%
Net income-$5.9M-0.7%
EPS (diluted)-$0.06+14.3%

Balance sheet

See full
Cash & equivalents$14.6M+36.7%
Total debt$5.3M-10.0%
Total equity$14.4M+399%
Total assets$54.0M+18.2%

Cash flow

See full
Operating cash flow-$3.4M-93.5%
CapEx$79.0K
Free cash flow-$3.5M

Valuation

See full
Market cap$168.11M-11.6%
Enterprise value$158.77M-15.9%
P/S5.4×-0.6×

Profitability

See full
Gross margin53.9%+0.5pp
Operating margin-71%-14.0pp
Net margin-69.5%-13.7pp
FCF margin-35.5%-2.4pp

Returns & leverage

See full
Return on equity-251.5%-29.9pp
Debt / equity0.4×-1.7×
Current ratio1.6×+0.5×

Where this comes from

Reported directly by Stereotaxis in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Stereotaxis’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stereotaxis's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Stereotaxis's depreciation?
Stereotaxis (STXS) reported depreciation of $159K in Q1 2026.
How has Stereotaxis's depreciation changed year-over-year?
Stereotaxis's depreciation increased by 1.9% year-over-year, from $156K to $159K.
What is the long-term trend for Stereotaxis's depreciation?
Over 4 years (2021 to 2025), Stereotaxis's depreciation has grown at a 55.9% compound annual growth rate (CAGR), from $106K to $626K.